Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. on January 25, 2017. The filing addresses corporate governance changes, specifically an expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board appointments and associated compensation.
Material Changes
- Board Expansion: The Board of Directors increased from six to eight members.
- New Appointments: Karen Ferrante, M.D., and Scott Jackson were appointed as directors effective immediately.
- Committee Assignments: Dr. Ferrante joined the Nominating and Corporate Governance Committee; Mr. Jackson joined the Compensation Committee.
- Director Compensation:
- Annual retainer: $35,000 for each new director.
- Committee retainers: $4,000 for Dr. Ferrante (Nominating and Corporate Governance) and $5,000 for Mr. Jackson (Compensation).
- Stock Options: Each received an option to purchase 20,000 shares at an exercise price of $18.52 per share (closing market price on the grant date).
- Vesting: Options vest in 12 substantially equal monthly portions beginning on the first monthly anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No risks, contingencies, or unusual items were disclosed in this specific report. The company confirmed there are no undisclosed arrangements or material interests involving the new directors.
Investor Verification Checklist
- Verify the qualifications and background of new directors Dr. Ferrante and Mr. Jackson.
- Confirm the impact of the new stock options (40,000 total shares) on potential dilution.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the board expansion.
- Check subsequent filings for the first vesting date of the granted options.